Market Overview:
The global herpes zoster ophthalmicus drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of herpes zoster ophthalmicus, rising awareness about the disease, and technological advancements in the field of herpes zoster ophthalmicus drugs. Based on type, the global herpes zoster ophthalmicus drug market can be segmented into oral drugs, topical drugs, injectable drugs, and other types. Oral drugs are expected to account for a major share of this market due to their high efficacy and ease of use. Topical drugs are also anticipated to witness significant growth during the forecast period owing to their ability to provide localized relief from symptoms associated with herpes zoster ophthalmicus. Injectable drugs are expected to register a higher CAGR than other types during the forecast period as they offer rapid relief from symptoms and have a longer duration of action than oral or topical medications. Based on application, hospitals pharmacies accounted for majority share of this market in 2017 owing large patient population base seeking treatment for HSV-related eye diseases in hospitals setting across developed countries such as UAS., Canada., France., Germany., Italy., Spain,. However,, retail pharmacies is projectedto grow at highest rate over next decade due tobetter accessibilityand affordabilityof these productsfor consumers across regions.
Product Definition:
Herpes Zoster Ophthalmicus is a viral infection of the eye that can cause blindness. It is caused by the same virus that causes chickenpox and shingles. The virus affects the optic nerve and can cause inflammation, scarring, and loss of vision. Herpes zoster ophthalmicus is a serious condition and requires prompt treatment.
Oral Drug:
Oral drug is a medication which is administered to the patient by mouth. It may be in solid or liquid form and may be flavored or non-flavored. The drug works faster when it's given intravenously, but oral drugs are preferred because they're more convenient for patients.
The global market for oral drugs was valued at over USD 485 billion in 2013.
Topical Drug:
A topical drug is a medication that is applied to the skin or taken by mouth. Topical drugs are used for treating diseases and conditions affecting the skin, eye, and mucous membranes of the mouth. Some of these medications may also be used to reduce inflammation caused by disease-causing bacteria.
The most common types of topical drugs are ointments, creams, lotions, gels.
Application Insights:
Based on application, the global market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacy held the largest share of over 70% in 2017. This is due to factors such as high usage rates of drugs for treating ophthalmic herpes zoster and presence of a large patient base suffering from ophthalmic herpetic disease across hospitals globally.
The availability of various brands in the market for OZO-TRE by Mylan N.V., Teva Pharmaceuticals USA Corporation, Pfizer Inc., Novartis AG and others has led to increased competition among hospitals regarding purchasing medicines which has resulted in low prices being charged by Hospitals for these medicines (as compared to retail).
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers, favorable reimbursement policies, and increasing prevalence of herpetic diseases are some factors driving the growth. In addition, growing awareness about early diagnosis is expected to fuel demand for OZD drugs in this region. According to an article published by NCBI in 2018 titled “Epidemiology and clinical features of herpes zoster ophthalmicusâ€, it was stated that approximately 1 million people suffer from HZO annually in the U.S., with 50% developing within 14 days after rash onset (i.e., prodrome).
Growth Factors:
- Increasing incidence of herpes zoster ophthalmicus (HZO) due to aging population
- Growing demand for HZO drugs owing to increasing awareness about the disease
- Rising number of clinical studies on new HZO drugs that are in pipeline
- Launch of novel and effective drugs for the treatment of HZO
- Emergence of targeted therapies for treating HZO
Scope Of The Report
Report Attributes
Report Details
Report Title
Herpes Zoster Ophthalmicus Drug Market Research Report
By Type
Oral Drug, Topical Drug, Injectable Drug, Herpes Zoster Ophthalmicus Dru
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Abbott, Novartis, GlaxoSmithKline, Fresenius, SteriMax, Cadila Pharmaceuticals, Shermco, TEVA, Cipla, Mylan, Foamix, Merck, Herpes Zoster Ophthalmicus Dru
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Herpes Zoster Ophthalmicus Drug Market Report Segments:
The global Herpes Zoster Ophthalmicus Drug market is segmented on the basis of:
Types
Oral Drug, Topical Drug, Injectable Drug, Herpes Zoster Ophthalmicus Dru
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott
- Novartis
- GlaxoSmithKline
- Fresenius
- SteriMax
- Cadila Pharmaceuticals
- Shermco
- TEVA
- Cipla
- Mylan
- Foamix
- Merck
- Herpes Zoster Ophthalmicus Dru
Highlights of The Herpes Zoster Ophthalmicus Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral Drug
- Topical Drug
- Injectable Drug
- Herpes Zoster Ophthalmicus Dru
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Herpes Zoster Ophthalmicus Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Herpes zoster ophthalmicus (HZO) is a rare complication of herpes simplex virus (HSV) infection that can occur in the eye. HZO is caused by reactivation of HSV from an inactive form to a more active form in the eye. This can lead to inflammation and damage to the eyes, which may require surgery. Treatment typically includes antiviral medication and pain relief.
Some of the major companies in the herpes zoster ophthalmicus drug market are Abbott, Novartis, GlaxoSmithKline, Fresenius, SteriMax, Cadila Pharmaceuticals, Shermco, TEVA, Cipla, Mylan, Foamix, Merck, Herpes Zoster Ophthalmicus Dru.
The herpes zoster ophthalmicus drug market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Herpes Zoster Ophthalmicus Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Herpes Zoster Ophthalmicus Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Herpes Zoster Ophthalmicus Drug Market - Supply Chain
4.5. Global Herpes Zoster Ophthalmicus Drug Market Forecast
4.5.1. Herpes Zoster Ophthalmicus Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Herpes Zoster Ophthalmicus Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Herpes Zoster Ophthalmicus Drug Market Absolute $ Opportunity
5. Global Herpes Zoster Ophthalmicus Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Type
5.3.1. Oral Drug
5.3.2. Topical Drug
5.3.3. Injectable Drug
5.3.4. Herpes Zoster Ophthalmicus Dru
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Herpes Zoster Ophthalmicus Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Herpes Zoster Ophthalmicus Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Herpes Zoster Ophthalmicus Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Herpes Zoster Ophthalmicus Drug Demand Share Forecast, 2019-2026
9. North America Herpes Zoster Ophthalmicus Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Type
9.7.1. Oral Drug
9.7.2. Topical Drug
9.7.3. Injectable Drug
9.7.4. Herpes Zoster Ophthalmicus Dru
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Herpes Zoster Ophthalmicus Drug Demand Share Forecast, 2019-2026
10. Latin America Herpes Zoster Ophthalmicus Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Type
10.7.1. Oral Drug
10.7.2. Topical Drug
10.7.3. Injectable Drug
10.7.4. Herpes Zoster Ophthalmicus Dru
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Herpes Zoster Ophthalmicus Drug Demand Share Forecast, 2019-2026
11. Europe Herpes Zoster Ophthalmicus Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Type
11.7.1. Oral Drug
11.7.2. Topical Drug
11.7.3. Injectable Drug
11.7.4. Herpes Zoster Ophthalmicus Dru
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Herpes Zoster Ophthalmicus Drug Demand Share, 2019-2026
12. Asia Pacific Herpes Zoster Ophthalmicus Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Type
12.7.1. Oral Drug
12.7.2. Topical Drug
12.7.3. Injectable Drug
12.7.4. Herpes Zoster Ophthalmicus Dru
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Herpes Zoster Ophthalmicus Drug Demand Share, 2019-2026
13. Middle East & Africa Herpes Zoster Ophthalmicus Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Herpes Zoster Ophthalmicus Drug Market Size and Volume Forecast by Type
13.7.1. Oral Drug
13.7.2. Topical Drug
13.7.3. Injectable Drug
13.7.4. Herpes Zoster Ophthalmicus Dru
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Herpes Zoster Ophthalmicus Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Herpes Zoster Ophthalmicus Drug Market: Market Share Analysis
14.2. Herpes Zoster Ophthalmicus Drug Distributors and Customers
14.3. Herpes Zoster Ophthalmicus Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbott
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Fresenius
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. SteriMax
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Cadila Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Shermco
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. TEVA
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Cipla
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Mylan
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Foamix
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Merck
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Herpes Zoster Ophthalmicus Dru
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
